Get Cash Back and $0 Commissions
+ The Power of TradeStation
PRNewswire 1-Nov-2018 8:30 AM
PR Newswire
SAN RAFAEL, Calif., Nov. 1, 2018
SAN RAFAEL, Calif., Nov. 1, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will host an R&D Day from 8:30am (ET) to 11:30am (ET) on Wednesday, November 7, 2018 in New York City. BioMarin management and external experts will provide an update to the investment community on the Company's development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases.
BioMarin R&D Day 2018 Agenda
Welcome and Opening Remarks
Vosoritide for Achondroplasia
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Regulatory Policy Advances at the Food and Drug Administration
PKU Gene Therapy Data and Program update; R&D Pipeline Deep Dive
Closing Statements
Live Video Webcast
Interested parties may access a live video webcast that will include audio and slides of the presentations here. A replay of the meeting will be archived on the site for at least one week.
For those who choose not to listen and view the event via webcast, dial-in information for the audio portion of the webcast can be accessed using:
USA: (913) 227-1201
USA /Canada (toll free): (866) 705-2554
Conference ID: 6342187
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.
Contacts: |
|
Investors |
Media |
Traci McCarty |
Debra Charlesworth |
BioMarin Pharmaceutical Inc. |
BioMarin Pharmaceutical Inc. |
(415) 455-7558 |
(415) 455-7451 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-highlight-breadth-of-innovative-development-pipeline-at-rd-day-on-november-7th-in-new-york-300741971.html
SOURCE BioMarin Pharmaceutical Inc.